Endocrinology, Vol 133, 1247-1251, Copyright © 1993 by Endocrine Society

ARTICLES

Effect of a major histocompatibility complex class I peptide on insulin- like growth factor-I receptor internalization and biological signaling

D Hsu and JM Olefsky
Department of Medicine, University of California-San Diego, La Jolla 92093.

Previous studies have shown that a peptide derived from the murine major histocompatibility complex class 1 (MHC-1) antigen inhibits insulin receptor internalization and enhances insulin action. Consequently, we have studied the effect of this peptide [Dk-(62-85)] derived from the MHC-1 antigen on insulin-like growth factor-I (IGF-I) internalization and action. When Chinese hamster ovary cells that overexpress human IGF-I receptors were incubated in the presence or absence of 30 microM Dk-(62-85), IGF-I internalization was inhibited by 43.9 +/- 1.7% (P < 0.005). This inhibitory effect was dose responsive, with a half-maximal effect at 8 microM and a maximal effect at 30 microM. The peptide did not affect IGF-I receptor autophosphorylation or ligand-induced phosphorylation of an endogenous substrate, pp185, in vivo. When added alone, the peptide increased glucose transport into Chinese hamster ovary cells by 66.3 +/- 16.0%, whereas when the peptide was added together with IGF-I, ligand-stimulated glucose transport was inhibited. In conclusion, 1) the MHC-1-derived peptide Dk-(62-85) inhibits IGF-I internalization in a dose-responsive fashion; 2) Dk-(62- 85) does not affect receptor kinase activity, as IGF-I receptor autophosphorylation and endogenous substrate phosphorylation are unaltered; and 3) Dk-(62-85) stimulates glucose transport by itself, but inhibits IGF-I stimulated transport.

This article has been cited by other articles:

				D. W. Andrews, M. Resnicoff, A. E. Flanders, L. Kenyon, M. Curtis, G. Merli, R. Baserga, G. Iliakis, and R. D. Aiken Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas J. Clin. Oncol., April 15, 2001; 19(8): 2189 - 2200. [Abstract] [Full Text] [PDF]

				J. C. Chow, G. Condorelli, and R. J. Smith Insulin-like Growth Factor-I Receptor Internalization Regulates Signaling via the Shc/Mitogen-activated Protein Kinase Pathway, but Not the Insulin Receptor Substrate-1 Pathway J. Biol. Chem., February 20, 1998; 273(8): 4672 - 4680. [Abstract] [Full Text] [PDF]

				K. Sugiura, M. Inaba, H. Hisha, K. Borisov, E. E. Sardiña, R. A. Good, and S. Ikehara Requirement of Major Histocompatibility Complex-Compatible Microenvironment for Spleen Colony Formation (CFU-S on day 12 but not on day 8) Stem Cells, November 1, 1997; 15(6): 461 - 468. [Abstract] [Full Text]

				T. Naranda, A. Goldstein, and L. Olsson A peptide derived from an extracellular domain selectively inhibits receptor internalization: Target sequences on insulin and insulin-like growth factor 1 receptors PNAS, October 14, 1997; 94(21): 11692 - 11697. [Abstract] [Full Text] [PDF]